-
ALC-0315 in the mRNA-LNP Delivery Landscape
2026-10-09
This 2026 review places ALC-0315 alongside MC-3 and SM-102 as screening-derived ionizable lipids, but it does not provide a direct head-to-head test of those materials. In the cited comparisons, poly(carboxybetaine)-lipid nanoparticles produced lower IL-6 and TNF-α secretion than PEG-LNPs in human PBMC co-incubation and maintained luciferase expression across four intravenous administrations. Separately, an ionizable-phospholipid series shifted reported mRNA delivery from liver toward spleen as hydrophobic tail length increased. These are comparator-specific findings, not evidence that ALC-0315 is superior across systems.
-
mRNA Reporter Output and Intracellular Restriction
2026-10-07
In zebrafish PAC2 and Chinese tongue sole CST cells, transient trim25 knockdown increased Cap1-m1Ψ-eGFP mRNA reporter-positive cells relative to a non-targeting siRNA control, from 19.27% to 74.63% in PAC2 and from 10.41% to 36.15% in CST. In PAC2 cells, the same comparison produced a smaller increase for pEGFP-N1 plasmid DNA, from 4.89% to 11.58%. The study therefore supports a distinction between extracellular delivery and post-delivery expression, but it does not test ALC-0315, defined lipid nanoparticles, RNA uptake, endosomal escape, or biodistribution.
-
SORT Polymers and Organ-Selective mRNA Delivery
2026-10-05
A 2026 mouse study found that adding tunable degradable SORT polymers to ionizable-lipid nanoparticles changed where Luc mRNA was functionally expressed: optimized lung hybrids produced 13- to 26-fold higher expression than 50% DOTAP Lung-SORT LNPs at the same dose, while liver- and spleen-directed hybrids improved or redirected expression relative to lipid-only 4A3-SC8 or SORT LNP comparators. The work also links polymer incorporation with cellular uptake, intracellular accumulation and endosomal escape, but it does not test ALC-0315 and does not establish long-term safety or the causal basis of organ tropism.
-
Carrier-Free mRNA Delivery by Mechanoporation
2026-10-02
In K562 suspension cells, vertical droplet squeezing produced more than 98% eGFP-expression-positive cells at 2, 10, and 20 μg/mL TriLink eGFP mRNA, with approximately 250-fold higher mean fluorescence intensity than the endocytosis/no-squeezing control at 24 hours. In a separate FITC-dextran assay, delivery remained approximately 99% across K562 densities of 3, 6, and 9 × 10^7 cells/mL, although mean fluorescence decreased modestly at the highest density. Because the study did not test an ionizable- or PEG-lipid nanoparticle, ALC-0315, or any LNP comparator, it supports a carrier-free physical-delivery benchmark rather than evidence of superiority over LNP-based mRNA delivery.
-
ALC-0315 LNPs: Nasal mRNA Delivery Tradeoffs
2026-09-30
This review does not test ALC-0315 directly. It summarizes an intranasal formulation using ALC-0315 and DOTMA at a 3:1 ratio that reportedly overcame the mucosal barrier and increased antigen production in the nasal airway, although the reviewed text does not identify a comparator. In a separate nebulized lung comparison, IR-11717 and IR-19-Py LNPs produced more efficient lung RNA trafficking than hPBAE carriers; that result was a trafficking comparison, not proof of superior translated reporter protein output. Together, the findings support evaluating functional expression, inflammatory tolerability, endosomal escape, and stability rather than treating tissue-associated RNA as a complete measure of delivery.
-
ALC-0315 LNPs for Cardiovascular mRNA Delivery
2026-09-28
A review of cardiovascular mRNA medicine lists DOPS/ALC-0315 LNPs as an intravenous delivery system for FAP CAR mRNA in a mouse ischemia–reperfusion model. It summarizes functional outcomes but does not provide a direct ALC-0315 formulation comparison or quantitative uptake, encapsulation, or biodistribution measurements.
-
Kinetic PEG Shedding Tunes mRNA-LNP Delivery
2026-09-25
This study tests whether controlling when PEG leaves an mRNA lipid nanoparticle can balance barrier transport with cell entry. Oxanorbornadiene linkers enabled temperature-triggered PEG shedding, with rapid shedding associated with stronger pulmonary mRNA expression after inhalation and intermediate shedding with higher tumor expression after intravenous dosing. The work examines PEG-lipid behavior in SM-102 LNPs; it does not test ALC-0315.
-
Serial LNP–mRNA Delivery in Human T Cells
2026-09-23
Ramamurthy et al. evaluate repeated ex vivo delivery of synthetic mRNA to primary human T cells using SM102-based lipid nanoparticles containing DOTAP and DOPE. The study links formulation composition with mRNA encapsulation, cellular entry, translated protein, endosomal trafficking, viable-cell yield, and CAR-T function, while showing that the tested platform is related to—but does not directly evaluate—ALC-0315.
-
ALC-0315 mRNA-LNPs in Oral Cancer Research
2026-09-22
This 2026 study evaluated an ALC-0315/DOPE/cholesterol lipid nanoparticle carrying survivin mRNA, alone or combined with a CTLA-4 inhibitor, in dendritic-cell, immune-cell, and healthy-mouse models. The formulation protected mRNA from RNase degradation, increased labeled-mRNA uptake, produced survivin protein, and induced immune responses, but the study did not establish direct endosomal escape, biodistribution, PEG-lipid performance, tumor-bearing efficacy, or long-term formulation stability.
-
Polyphenol Nanoparticles for mRNA Delivery
2026-09-21
Lu et al. developed tannic-acid/polyarginine nanoparticles for mRNA delivery and compared their functional output with an SM-102 lipid nanoparticle formulation. The polyphenol system achieved high mRNA encapsulation, pH-responsive release, substantial fluorescent-particle association with cells, and reporter-mRNA expression, although its mRNA expression was lower than that of the SM-102 comparator. The study is relevant to ALC-0315 and related lipid nanoparticle research as a non-lipid benchmark, but it did not test ALC-0315, organ targeting, or in vivo biodistribution.
-
Dual-pKa LNPs for Lung-Selective mRNA Delivery
2026-09-18
Lim et al. investigated fSG5, a DOPE-containing lipid nanoparticle built from the dual-transition ionizable lipid SG5, for systemic lung-selective mRNA delivery. The study connects apparent pKa behavior with reporter-mRNA expression, endosomal trafficking, computational membrane interactions, tolerability, and Nrf2 mRNA activity in acute lung injury. It is a related ionizable-LNP study rather than a direct evaluation of ALC-0315.
-
PET Tracking of mRNA Antigen Expression
2026-09-16
This research highlight describes a PET reporter system designed to measure translated mRNA vaccine antigen in vivo. An eDHFR tag encoded with the antigen binds the radiotracer trimethoprim, allowing whole-body imaging of antigen expression rather than simply tracking lipid nanoparticles, labeled RNA, or cellular uptake. The supplied text does not identify an ALC-0315 formulation or provide formulation-level delivery data.
-
DOTAP for Nucleic Acid Delivery and Assay Design
2026-09-08
DOTAP provides a practical cationic-lipid platform for transient gene expression, RNA perturbation, and formulation screening. This guide connects formulation choices with controls, troubleshooting, and the immune-metabolic questions raised by recent nano-zoledronate research.
-
EZ Cap™ Cre mRNA: A Functional Delivery Benchmark
2026-08-28
EZ Cap™ Cre mRNA (m1Ψ) can do more than drive transient recombination: it can help researchers dissect mRNA delivery, translation, and functional protein activity. This article connects the reagent’s molecular design with practical assay decisions inspired by emerging extrahepatic delivery platforms.
-
DOTAP: Cationic Lipid for Nucleic Acid Delivery
2026-08-19
1,2-Dioleoyl-3-trimethylammonium-propane chloride, also called DOTAP, is a synthetic cationic lipid for DNA, RNA, and antisense oligonucleotide delivery. Its electrostatic complexation and formulation flexibility support transient gene expression, functional genomics, and lipid nanoparticle optimization, but performance remains formulation- and cell-type-dependent.